Glucagon-like peptide-2 and its therapeutic use
Assignee1149336 Ontario Inc.
InventorDaniel J. Drucker
Life of this patent
Estimating the term…
Abstract
Glucagon-like peptide 2, a product of glucagon gene expression, has been identified as a gastrointestinal tissue growth factor. Its effects on the growth of small intestine and on pancreatic islets are described. Its formulation as a pharmaceutical, and its therapeutic use in treating bowel tissue disorders and in treating diabetes, are described.
Claims80
A pharmaceutical composition, comprising a GLP-2, or a pharmaceutically acceptable salt thereof, and a carrier, said carrier being a pharmaceutically acceptable carrier other than saline solution.
A pharmaceutical composition, comprising a GLP-2, or a pharmaceutically acceptable salt thereof, other than human GLP-2(1-34), and a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising a GLP-2, or a pharmaceutically acceptable salt thereof, other than human GLP-2(1-34) or human GLP-2(1-33), and a pharmaceutically acceptable carrier.
A method for promoting the growth of small intestine tissue in a patient in need thereof, comprising the step of administering to the patient an effective amount of a pharmaceutical composition comprising a GLP-2 or a pharmaceutically acceptable salt thereof to promote the growth of small intestine tissue.
A method for promoting the growth of pancreatic islets in a patient in need thereof, comprising the step of administering to the patient an effective amount of a pharmaceutical composition comprising a GLP-2 or a pharmaceutically acceptable salt thereof to promote the growth of pancreatic islets.
A method for treating a patient suffering from type 1 diabetes, comprising the step of administering to the patient an effective amount of a pharmaceutical comprising a GLP-2 or a pharmaceutically acceptable salt thereof to promote the growth of pancreatic islets.
A method for promoting the growth of gastrointestinal tissue in a patient in need thereof, comprising the step of administering to the patient an effective amount of a pharmaceutical composition comprising a GLP-2 or a pharmaceutically acceptable salt thereof to promote the growth of gastrointestinal tissue.
A pharmaceutical composition comprising a GLP-2, or a pharmaceutically acceptable salt thereof, wherein the GLP-2 is of the formula:
- R1-[Y]m-His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-aa1-Leu-Asp-aa2-Leu -Ala-aa3-Arg-Asp-Phe-Ile-Asn-Trp-Leu-aa4-aa5-Thr-Lys-Ile-Thr-Asp-[X]n-R2 (SEQ ID NO:
- 4)
- wherein:
- aa1 is a neutral, polar, large and nonaromatic amino acid residue;
- aa2 is a neutral and polar amino acid residue;
- aa3 is a neutral amino acid residue;
- aa4 is a neutral, polar, large and nonaromatic amino acid residue;
- aa5 is a neutral or basic amino acid residue;
- X is Arg, Lys, Arg-Lys or Lys-Lys;
- Y is Arg or Arg-Arg;
- m is 0 or 1;
- n is 0 or 1;
- R1 is H or an N-terminal blocking group;
- and
- R2 is OH or a C-terminal blocking group;
- wherein the GLP-2 is other than human GLP-2(1-34).
A pharmaceutical composition comprising a GLP-2, or a pharmaceutically acceptable salt thereof, wherein the GLP-2 is of the formula:
- R1-[Y]m-His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-aa1-Leu-Asp-aa2-Leu -Ala-aa3-Arg-Asp-Phe-Ile-Asn-Trp-Leu-aa4-aa5-Thr-Lys-Ile-Thr-Asp-[X]n-R2 (SEQ ID NO:
- 4)
- wherein:
- aa1 is a neutral, polar, large and nonaromatic amino acid residue;
- aa2 is a neutral and polar amino acid residue;
- aa3 is a neutral amino acid residue;
- aa4 is a neutral, polar, large and nonaromatic amino acid residue;
- aa5 is a neutral or basic amino acid residue;
- X is Arg, Lys, Arg-Lys or Lys-Lys;
- Y is Arg or Arg-Arg;
- m is 0 or 1;
- n is 0 or 1;
- R1 is H or an N-terminal blocking group;
- and
- R2 is OH or a C-terminal blocking group;
- wherein the GLP-2 is other than human GLP-2(1-34) or human GLP-2 (1-33).
Dependencies are inferred from the claim text.